BiotechTube
Home/Pipeline/Acellular Secretome

Acellular Secretome

Not Specified

PreclinicalActive

Key Facts

Indication
Not Specified
Phase
Preclinical
Status
Active
Company
Arugula Sciences

About Arugula Sciences

Arugula Sciences is a private, clinical-stage biotech leveraging the therapeutic potential of umbilical cord-derived mesenchymal stem cells (UC-MSCs) and acellular products. The company's lead program, Signature Cord Prime™, is in an FDA Phase 1 trial for knee osteoarthritis, with another Phase 1 study approved for big toe osteoarthritis. Founded in 2018, Arugula is pre-revenue and is building a platform around perinatal tissue biologics to treat a range of degenerative conditions, positioning itself in the competitive but high-growth cell and gene therapy sector.

View full company profile

Therapeutic Areas

OrthopedicsInflammatory DiseasesDegenerative Diseases

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved